Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Abstract: Neuroendocrine tumors (NETs) occur in various regions of the body and present with complex clinical and biochemical phenotypes. The molecular underpinnings that give rise to such varied manifestations have not been completely deciphered. The management of neuroendocrine tumors (NETs) involves surgery, locoregional therapy, and/or systemic therapy. Several forms of systemic therapy, including platinum-based chemotherapy, temozolomide/capecitabine, tyrosine kinase inhibitors, mTOR inhibitors, and peptide receptor radionuclide therapy have been extensively studied and implemented in the treatment of NETs. However, the potential of immune checkpoint inhibitor (ICI) therapy as an option in the management of NETs has only recently garnered attention. Till date, it is not clear whether ICI therapy holds any distinctive advantage in terms of efficacy or safety when compared to other available systemic therapies for NETs. Identifying the characteristics of NETs that would make them (better) respond to ICIs has been challenging. This review provides a summary of the current evidence on the value of ICI therapy in the management of ICIs and discusses the potential areas for future research.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors ; day:02 ; month:09 ; year:2022
Hormone and metabolic research ; (02.09.2022)
- Beteiligte Personen und Organisationen
-
Gubbi, Sriram
Vijayvergia, Namrata
Yu, Jian Q.
Klubo-Gwiezdzinska, Joanna
Koch, Christian A.
- DOI
-
10.1055/a-1908-7790
- URN
-
urn:nbn:de:101:1-2022111012022048403910
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gubbi, Sriram
- Vijayvergia, Namrata
- Yu, Jian Q.
- Klubo-Gwiezdzinska, Joanna
- Koch, Christian A.
Ähnliche Objekte (12)
Neurotoxicities associated with immune checkpoint inhibitor therapy
Safety of sequential immune checkpoint inhibitors after prior immune therapy
Antibiotic therapy and outcome from immune-checkpoint inhibitors
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
Neurotoxicities associated with immune checkpoint inhibitor therapy
Safety of sequential immune checkpoint inhibitors after prior immune therapy
Antibiotic therapy and outcome from immune-checkpoint inhibitors
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
Neurotoxicities associated with immune checkpoint inhibitor therapy
Safety of sequential immune checkpoint inhibitors after prior immune therapy
Antibiotic therapy and outcome from immune-checkpoint inhibitors
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy